In silico drug discovery uses computational methods to identify and optimize drug candidates. Virtual screening computationally evaluates large compound libraries against a target structure or pharmacophore to select compounds for experimental testing. It reduces the cost and time of drug discovery by focusing experimental resources on the most promising candidates.
Structure-based virtual screening uses the three-dimensional structure of the target protein. Molecular docking predicts the binding pose and affinity of each compound in the target binding site. Docking algorithms sample ligand conformations and orientations, while scoring functions estimate binding free energy. Common docking programs include AutoDock Vina, Glide, GOLD, and Dock.
Docking success depends on the quality of the protein structure, proper preparation including protonation state assignment and water molecule placement, and the accuracy of the scoring function. Consensus scoring using multiple scoring functions improves hit rates. Post-docking analysis includes visual inspection of binding poses and interaction analysis.
Ligand-based virtual screening does not require the target structure. Pharmacophore models capture the essential spatial arrangement of functional groups required for activity. Quantitative structure-activity relationship models correlate molecular descriptors with biological activity. Similarity searching using molecular fingerprints identifies compounds related to known active molecules.
Machine learning methods have transformed computational drug discovery. Random forests, support vector machines, and deep neural networks predict activity, toxicity, and ADME properties. Graph neural networks operating on molecular graphs capture structural information for property prediction. Generative models including variational autoencoders and generative adversarial networks design novel chemical structures with desired properties.
Hit-to-lead optimization uses free energy perturbation and thermodynamic integration to guide structural modifications. These methods calculate relative binding affinities between related compounds with accuracy approaching experimental error. Alchemical free energy methods are increasingly used in lead optimization.
Applications have yielded approved drugs including the HIV protease inhibitors designed using structure-based methods. Virtual screening identified novel leads for kinases, GPCRs, and enzymes. In silico ADME prediction reduces late-stage attrition.
